AG Scientific

Executive Summary

AG Scientific is a privately held supplier of high-purity biochemicals, antibiotics, and research reagents for the life sciences industry. Founded in 1997 and headquartered in San Diego, the company serves as a critical partner for academic, diagnostic, and pharmaceutical research laboratories. Its product portfolio includes essential tools such as selection antibiotics (e.g., Blasticidin S, Hygromycin B), enzyme substrates (e.g., X-GAL), and other specialized biochemicals. The company has maintained a steady presence in the market for nearly three decades, leveraging its expertise in high-purity manufacturing to support a wide range of research applications. As a private entity, AG Scientific does not disclose financials, but its longevity suggests consistent demand from its niche customer base. Looking ahead, AG Scientific is well-positioned to benefit from the growing global demand for research reagents and biochemicals, driven by expansion in diagnostics, biopharmaceutical R&D, and academic research. The company may explore opportunities to broaden its product line, particularly in areas like gene editing and cell therapy, where high-purity reagents are critical. However, as a small private firm, it faces competitive pressure from larger suppliers such as Thermo Fisher and Merck. Its ability to maintain quality and customer relationships will be key to sustaining growth. Overall, AG Scientific represents a stable but low-growth opportunity in the life sciences supply chain.

Upcoming Catalysts (preview)

• Q4 2026Launch of new high-purity reagents for cell and gene therapy research65% success
• Q1 2027Expansion of distribution partnerships in Asia-Pacific markets55% success
• Q2 2027Introduction of custom synthesis services for biopharma clients50% success